

**SYNTHESIS, STRUCTURE AND ANTIMICROBIAL
PROPERTIES OF NEW SILVER(I)- AND
PALLADIUM(II)-*N*-HETEROCYCLIC CARBENE
COMPLEXES DERIVED FROM
[BENZ]IMIDAZOL-2-YLIDENES**

PATRICK O. ASEKUNOWO

**UNIVERSITI SAINS MALAYSIA
2015**

**SYNTHESIS, STRUCTURE AND ANTIMICROBIAL
PROPERTIES OF NEW SILVER(I)- AND
PALLADIUM(II)-*N*-HETEROCYCLIC CARBENE
COMPLEXES DERIVED FROM
[BENZ]IMIDAZOL-2-YLIDENES**

By

PATRICK O. ASEKUNOWO

**Thesis submitted in fulfilment of the requirements for the degree of Doctor of
Philosophy**

May 2015

DEDICATION

This thesis is dedicated to

- *The memory of my father.*
- *My late sister who passed on a love of reading and respect for education.*
- *My loving mother.*
- *My lovely wife and children.*

ACKNOWLEDGMENTS

I thank God for the divine blessings showered on me. I would like to express my deepest gratitude to my advisor, Dr. Rosenani A. Haque, for her excellent guidance, caring and providing me with an enabling atmosphere for doing research. I especially thank her for her kindness and for being so patient and understanding. It has been a great learning experience! I could not have imagined having a better advisor and mentor for my doctorate study. For everything you've done for me, Dr. Rose, I thank you.

I would also like to thank all staff of the School of Chemical Sciences for providing an enabling research environment, School of Physics and School of Biological Sciences-USM for their help and for the use of necessary equipments. I am also thankful to Mr. Zahari for his support and cooperation on NMR. I also want to acknowledge the assistance of Mustaquim from the crystallography section for recording numerous X-ray data and for refining X-ray structures.

I would like to thank the members of Dr Rose research group, for all their support over the years. Fatima, Zetti, Hafiza, Suzy and Tabinda. In particular, thanks to Dr. Mohammad and Dr. Adnan, their friendship, humour and support made a very stressful research environment tolerable and even fun at times. I want to give special thanks to Dr. Srinivasa for his scientific advice and knowledge and many insightful discussions and suggestions. I am also very grateful to Dr Rizal for all his help with some tricky crystal structures and other research projects. I would like to thank Dr. Amirul of the School of Biological Sciences for providing the bacterial strains used in this study. To my friend Faisal of microbiology lab, you put up with my seemingly endless tirade of questions and were always at hand when I needed more answers. Thank you for all the sleepless nights, which was very instrumental in helping me to

turn out this thesis on time. I would also like to gratefully acknowledge Institute of Postgraduate Study, Universiti Sains Malaysia for the graduate assistant award.

Finally, I would like to thank my mum for all she sacrificed for us and my wife for her support, encouragement, quiet patience and unwavering love were undeniably a testament in itself of her unyielding devotion and love, and for allowing me time away from family stuff to get this thing completed.

TABLE OF CONTENTS

	Page
Dedication	ii
Acknowledgments	iii
Table of Contents	v
List of Figures	xii
List of Schemes	xix
List of Tables	xxi
List of Abbreviations	xxv
List of publication and conferences	xxvii
Abstrak	xxix
Abstract	xxxix
CHAPTER 1 – INTRODUCTION	1
1.1 <i>N</i> -Heterocyclic Carbenes (NHCs)	1
1.2 Background	2
1.3 Structural diversities and stability	3
1.4 Synthesis of azolium salts: the NHC precursors	5
1.4.1 Nucleophilic substitution	5
1.4.2 Multi components one step reaction	6
1.5 Preparation of NHC complexes	7
1.6 Functionalized NHC complexes	11
1.6.1 Functionalized NHCs and metal complexes containing nitrogen donors	12
1.6.2 Functionalized NHCs and metal complexes containing oxygen Donors	14
1.7 Antibiotics	15
1.8 Biological applications of Ag(I)- and Pd(II)-NHC complexes	18

1.8.1	Background	18
1.8.2	Biological applications of Ag(I)-NHC complexes	21
1.8.3	Biological application of Pd(II)-NHC complexes	24
1.9	Aims and objectives of the research	26
CHAPTER 2 – EXPERIMENTAL		28
2.1	General Procedures	28
2.2	Materials	28
2.3	Synthesis of mono-[benz]imidazolium salts (1-15)	29
2.3.1	1-methoxyethyl-3-propylimidazolium hexafluorophosphate (1)	29
2.3.2	1-methoxyethyl-3-butylimidazolium hexafluorophosphate (2)	30
2.3.3	1-methoxyethyl-3-allylimidazolium hexafluorophosphate (3)	31
2.3.4	1-methoxyethyl-3-pentylimidazolium hexafluorophosphate (4)	32
2.3.5	1-ethyl-3-allylimidazolium hexafluorophosphate (5)	33
2.3.6	1-pentyl-3-allylimidazolium hexafluorophosphate (6)	34
2.3.7	1-pentyl-3-benzylimidazolium hexafluorophosphate (7)	35
2.3.8	1,3-bis(benzylbenimidazolium)hexafluorophosphate (8)	36
2.3.9	1-pentyl-3-benzylbenzimidazolium hexafluorophosphate (9)	37
2.3.10	1-hexyl-3-benzylbenzimidazolium bromide (10)	38
2.3.11	1-ethyl-3-allylbenzimidazolium hexafluorophosphate (11)	39
2.3.12	1-pentyl-3-allylbenzimidazolium hexafluorophosphate (12)	41
2.3.13	1-cyanopropyl-3-allylbenzimidazolium bromide (13)	41
2.3.14	1-cyanopropyl-3-butylbenzimidazolium bromide (14)	43
2.3.15	1-cyanopropyl-3-benzylbenzimidazolium bromide (15)	43
2.4	Synthesis of bis-[benz]imidazolium salts (16-25)	44
2.4.1	1,4-bis(3-methoxyethylimidazol-1-ylmethyl)benzene bis (hexafluorophosphate) (16)	44

2.4.2	2,6-bis(3-methoxyimidazol-1-ylmethyl)pyridine bis (hexafluorophosphate) (17)	46
2.4.3	2,6-bis(3-allylimidazol-1-ylmethyl)pyridine bis (hexafluorophosphate) (18)	47
2.4.4	1,4-bis(3-pentylimidazol-1-ylmethyl)benzene bis (hexafluorophosphate) (19)	48
2.4.5	1,4-bis(3-hexylimidazol-1-ylmethyl)benzene bis (hexafluorophosphate) (20)	50
2.4.6	1,1-diallyl-3,3-propylene diimidazolium dibromide (21)	50
2.4.7	1,1-diallyl-3,3-propylene dibenzimidazolium) dibromide (22)	51
2.4.8	2,6-bis(3-allyl-benzimidazol-1-ylmethyl)pyridine dibromide (23)	52
2.4.9	2,6-bis(3-pentylbenzimidazol-1-ylmethyl)pyridine dibromide (24)	54
2.4.10	2,6-bis(3-hexylbenzimidazol-1-ylmethyl)pyridine dibromide (25)	55
2.5	Synthesis of mononuclear Ag(I)-NHC complexes (26-40)	56
2.5.1	1-methoxyethyl-3-propylimidazolium-silver(I) hexafluorophosphate (26)	56
2.5.2	1-methoxyethyl-3-butylimidazolium-silver(I) hexafluorophosphate (27)	57
2.5.3	1-methoxyethyl-3-allylimidazolium-silver(I) hexafluorophosphate (28)	58
2.5.4	1-methoxyethyl-3-pentylimidazolium-silver(I) hexafluorophosphate (29)	59
2.5.5	1-ethyl-3-allylimidazolium-silver(I) hexafluorophosphate (30)	60
2.5.6	1-pentyl-3-allylimidazolium-silver(I) hexafluorophosphate (31)	61
2.5.7	1-pentyl-3-benzylimidazolium-silver(I) hexafluorophosphate (32)	62
2.5.8	1,3-bis(benzylbenzimidazolium-silver(I) hexafluorophosphate (33)	63
2.5.9	1-pentyl-3-benzylbenzimidazolium-silver(I) hexafluorophosphate (34)	64
2.5.10	1-hexyl-3-benzylbenzimidazolium-silver(I) hexafluorophosphate (35)	65
2.5.11	1-ethyl-3-allylbenzimidazolium-silver(I) hexafluorophosphate (36)	66
2.5.12	1-pentyl-3-allylbenzimidazolium-silver(I) hexafluorophosphate (37)	68
2.5.13	1-cyanopropyl-3-allylbenzylbenzimidazolium-silver(I) hexafluorophosphate (38)	69

2.5.14	1-cyanopropyl-3-butylbenzimidazolium-silver(I) hexafluorophosphate (39)	70
2.5.15	1-cyanopropyl-3-benzylbenzimidazolium-silver(I) hexafluorophosphate (40)	71
2.6	Synthesis of binuclear Ag(I)-NHC complexes (41-50)	72
2.6.1	1,4-bis(3-methoxyethylimidazol-ylmethyl)benzene disilver(I) bis(hexafluorophosphate) (41)	72
2.6.2	2,6-bis(3-methoxyethylimidazol-1-ylmethyl)pyridine disilver(I) bis (hexafluorophosphate) (42)	73
2.6.3	2,6-bis(3-allylimidazol-1-ylmethyl)pyridine disilver(I) bis(hexafluorophosphate) (43)	74
2.6.4	1,4-bis(3-pentylimidazol-1-ylmethyl)benzene disilver(I) bis (hexafluorophosphate) (44)	75
2.6.5	1,4-bis(3-hexylimidazol-1-methyl)benzene disilver(I) bis (hexafluorophosphate) (45)	77
2.6.6	1,1-diallyl-3,3-propylene diimidazolium disilver(I) bis(hexafluorophosphate) (46)	78
2.6.7	1,1-diallyl-3,3-propylene dibenzimidazoliumdisilver(I) bis(hexafluorophosphate) (47)	79
2.6.8	2,6-bis(3-allylbenzimidazol-1-ylmethyl)pyridinedisilver(I) bis(hexafluorophosphate) (48)	80
2.6.9	2,6-bis(3-pentylbenzimidazol-1-ylmethyl)pyridine disilver bis(hexafluorophosphate) (49)	82
2.6.10	2,6-bis(3-hexylbenzimidazol-1-ylmethyl)pyridine disilver bis(hexafluorophosphate) (50)	83
2.7	Synthesis of CNC pincer palladium(II)-NHC complexes	84
2.7.1	2,6-bis(3-methoxyethylimidazol-1-ylmethyl)pyridine palladium(II) hexafluorophosphate (51)	84
2.7.2	2,6 -bis(3-allylimidazol-1-ylmethyl)pyridine palladium(II) hexafluorophosphate (52)	85
2.7.3	2,6 -bis(3-allylbenzimidazol-1-ylmethyl)pyridine palladium(II) hexafluorophosphate (53)	86
2.7.4	2,6-bis(3-pentylbenzimidazol-1-ylmethyl)pyridine palladium(II) hexafluorophosphate (54)	87

2.7.5	2,6-bis(3-hexylbenzimidazol-1-ylmethyl)pyridine palladium(II) hexafluorophosphate (55)	89
2.8	Anti-bacterial activity	90
2.8.1	Media, Chemicals, Antibiotic and Bacterial strains	90
2.8.2	Preparation of Media and Reagents	90
2.8.3	Anti-bacterial assay	91
2.8.3.1	Disc diffusion method (zone of inhibition)	91
2.8.3.2	Minimum inhibitory concentration (MIC)	93
2.8.3.3	Minimum bactericidal concentration (MBC)	93
2.9	Gel electrophoresis	94
2.10	Lipophilicity assay	94
	CHAPTER THREE – [BENZ]IMIDAZOLIUM SALTS	96
3.1	Introduction	96
3.2	Results and discussion	99
3.2.1	Synthesis of mono-[benz]imidazolium salts (1-15)	99
3.2.2	FTIR spectroscopy	104
3.2.3	NMR spectroscopy	106
3.2.4	Synthesis of bis-[benz]imidazolium salts (16-25)	114
3.2.5	FTIR spectroscopy	118
3.2.6	NMR spectra of the prepared salts (16-25)	119
3.2.7	X-ray crystallography	126
	CHAPTER FOUR-SILVER(I)-NHC COMPLEXES	131
4.1	Introduction	131
4.2	Results and discussion	133
4.2.1	Synthesis of mononuclear Ag(I)-NHC complexes (26-40)	133
4.2.2	FTIR spectroscopy for [benz]imidazolium based mononuclear Ag(I)-NHC complexes (16-25)	136

4.2.3	NMR spectroscopy for imidazolium based mononuclear Ag(I)-NHC complexes (26-32)	138
4.2.4	NMR spectroscopy for benzimidazolium based mononuclear Ag(I)-NHC complexes (33-40)	145
4.2.5	X-ray crystallography	150
4.2.6	Synthesis of dinuclear Ag(I)-NHC complexes (41-50)	161
4.2.7	FTIR spectroscopy for the binuclear Ag(I)-NHC complexes (41-50)	163
4.2.8	NMR spectroscopy for imidazolium based binuclear Ag(I)-NHC complexes(41-46)	165
4.2.9	NMR spectroscopy for benzimidazolium based binuclear Ag(I)-NHC complexes (47-50)	169
4.2.10	Hydrolysis test	170
4.2.11	X-ray crystallography	173
CHAPTER FIVE-CNC Pincer Palladium(II)-NHC Complexes		182
5.1	Introduction	182
5.2	Results and discussion	183
5.2.1	Synthesis of CNC pincer Pd(II)-NHC complexes	183
5.2.2	FTIR spectroscopy for Pd(II)-NHC complexes (51-55)	185
5.2.4	NMR spectroscopy for Pd(II)-NHC complexes (51-52)	186
5.2.5	X-ray crystallography	190
CHAPTER SIX-ANTIBACTERIAL STUDY		198
6.1	Introduction	198
6.1.1	overview	198
6.1.2	MIC, MBC and Zone of inhibition	198
6.1.3	The role of chelation in antibacterial activity	200
6.1.4	The role of substituents in antibacterial activity	200
6.1.5	Metal complexes as chemical nucleases	201
6.2	Results and discussion	201

6.2.1	Antibacterial test of mononuclear Ag(I)-NHC complexes (26-40)	202
6.2.2	Preliminary nuclease activities of mononuclear Ag(I)-NHC complexes	211
6.2.3	Antibacterial test of binuclear Ag(I)-NHC complexes (41-50)	213
6.2.4	Preliminary nuclease activities of binuclear Ag(I)-NHC complexes	219
6.2.5	Antibacterial test of Pd(II)-NHC complexes (51-55)	220
6.2.6	Preliminary nuclease activities of Pd(II)-NHC complexes (51-55)	224
6.3	Lipophilicity	226
CHAPTER 7 - CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK		229
7.1	Conclusions	229
7.2	Recommendations for future work	233
REFERENCES		234
APPENDIX		265

LIST OF FIGURE

		Page
Figure 1.1	(a) Position of the carbene carbon (b) order of electron donating power.	2
Figure 1.2	Types of NHC ligands.	4
Figure 1.3	Electronic stabilization of NHCs.	5
Figure 1.4	Pyridine NHC ligands.	12
Figure 1.5	Examples of N-functionalized NHC precursors.	13
Figure 1.6	Examples of N-functionalized Ag(I)-NHC and Pd(II)-NHC complexes.	14
Figure 1.7	Examples of O-functionalised Ag(I)-NHC and Pd(II)-NHC complexes.	15
Figure 1.8	Staphylococcal lesions associated with the kidney.	20
Figure 1.9	Structures of sulfadiazine (XVIII) and silver sulfadiazine (XIX).	23
Figure 1.10	The first Ag(I)-NHC complexes used as antimicrobials.	23
Figure 1.11	Structures of Ag(I)-NHC complexes exhibiting significant antimicrobial activity.	23
Figure 1.12	Structures of Pd(II)-NHC complexes exhibiting stronger inhibitory effect than cisplatin.	25
Figure 1.13	Representative structure of pincer Pd(II)-NHC complexes.	26
Figure 3.1	Tautomeric structures of imidazole.	96
Figure 3.2	The structure of benzimidazole.	97
Figure 3.3	Tautomeric structures of benzimidazole.	97
Figure 3.4	Representation of imidazolium and benzimidazolium salts.	98

Figure 3.5	Structures of the mono-[benz]imidazolium salts (1-15).	100
Figure 3.6	Representative FTIR spectrum of salt 14 .	105
Figure 3.7	¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum for salt 3 . *H ₂ O and **DMSO.	107
Figure 3.8	¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum for salt 6 . *H ₂ O and ** DMSO.	108
Figure 3.9	¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum for salt 11 . *H ₂ O and **DMSO.	108
Figure 3.10	¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum for salt 12 . *H ₂ O and **DMSO.	109
Figure 3.11	Structures of bis-[benz]imidazolium salts (16-25).	115
Figure 3.12	Representative FTIR spectrum of salt 16 .	119
Figure 3.13	Portion of ¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum of salt 18 .	121
Figure 3.14	¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) spectrum of salt 19 . *H ₂ O and **DMSO.	121
Figure 3.15	Portion of ¹ H NMR (<i>d</i> ₆ -DMSO, 500 MHz) of salt 23 .	122
Figure 3.16	Cationic structure of 11 . Hexafluorophosphate anion in the lattice atoms is omitted.	126
Figure 3.17	Cationic structure of 16 with the ellipsoids shown at 50% probability.	127
Figure 3.18	(a) Cationic structure of 18 with thermal ellipsoids shown at 50% probability. Hexafluorophosphate anions in the lattice and hydrogen atoms omitted for clarity. (b) Face-to-face π - π interaction between two adjacent molecules.	128
Figure 3.19	(a) Molecular structure of 23 with thermal ellipsoids shown at 50% probability. Hydrogen atoms. (b) Supramolecular interactions in 23 , resulting in the formation of 1D network. Symmetry elements used: ⁱ = 2-x, -y, 1-z; ⁱⁱ = 1-x, y-1, 2-z.	129
Figure 4.1	Representative FTIR spectra of Ag(I)-NHC complex 40 .	137
Figure 4.2	¹ H NMR spectra (<i>d</i> ₆ -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between (a) salt 3 and Ag ₂ O to obtain (b) mononuclear Ag(I)-NHC complex 28 . ** DMSO and *H ₂ O.	138

Figure 4.3	^{13}C NMR spectra (d_6 -DMSO, 500 MHz) indicating the changes in chemical shift of the carbene (C2) carbon after successful reaction between (a) salt 3 and Ag_2O to obtain (b) mononuclear Ag(I)-NHC complex 28 .	140
Figure 4.4	^1H NMR spectra (d_6 -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between (a) salt 6 and Ag_2O to obtain (b) mononuclear Ag(I)-NHC complex 31 . $^{**}\text{DMSO}$ and $^*\text{H}_2\text{O}$.	141
Figure 4.5	^{13}C NMR spectra (d_6 -DMSO, 125 MHz) indicating the changes in chemical shift of C2 after successful reaction between (a) salt 6 and Ag_2O to obtain (b) mononuclear Ag(I)-NHC complex 31 .	142
Figure 4.6	^1H NMR spectra (d_6 -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between (a) salt 9 and Ag_2O to obtain (b) mononuclear Ag(I)-NHC complex 34 . $^{**}\text{DMSO}$ and $^*\text{H}_2\text{O}$.	146
Figure 4.7	^{13}C NMR spectra (d_6 -DMSO, 125 MHz) indicating the changes in chemical shift of C2 after successful reaction between (a) salt 9 and Ag_2O to obtain (b) mononuclear Ag(I)-NHC complex 34 . $^{**}\text{DMSO}$ and $^*\text{H}_2\text{O}$.	147
Figure 4.8	Selected region of ^{13}C NMR spectrum showing appearance of two doublets after successful reaction between 9 and Ag_2O to get mononuclear Ag(I)-NHC complex 34 .	148
Figure 4.9	Cationic structure of 26 with the ellipsoids shown at 50% probability. Hydrogen atoms and PF_6 have been omitted for clarity. Atom C15 was refined isotropically due to disordered over two positions.	150
Figure 4.10	Cationic structure of 28 with ellipsoids shown at 50% probability. Hydrogen atoms and PF_6 anion in the lattice were omitted for clarity.	152
Figure 4.11	Cationic structure of 30 with ellipsoids shown at 50% probability. Hydrogen atoms and PF_6 anion in the lattice were omitted for clarity.	153
Figure 4.12	Cationic structure of 33 with ellipsoids shown at 50% occupancies. Hydrogen atoms and PF_6 anion in the lattice omitted for clarity. Symmetry element used: $i = 1-x, 1-y, 1-z$.	154

Figure 4.13	Cationic structure of 34 with ellipsoids shown at 50% occupancies. Hydrogen atoms and PF ₆ anion in the lattice omitted for clarity. Symmetry element used: $i = 1-x, 1-y, 1-z$.	155
Figure 4.14	Cationic structure of 35 with ellipsoids shown at 50% occupancies. Hydrogen atoms and PF ₆ anion in the lattice omitted for clarity.	156
Figure 4.15	(a) Cationic structure of 36 with the ellipsoids shown at 50% probability. Symmetry element used: $i = -x, y, \frac{1}{2}-z$. (b) Back-to-back π - π interactions between benzimidazole rings.	157
Figure 4.16	(a) Cationic structure of 38 with ellipsoids shown at 50% probability. Hydrogen atoms and PF ₆ anions were omitted for clarity. (b) The Ag \cdots N3 ⁱ interaction in crystal structure in 38 . Symmetry element used: $i = -x-1/2, 3/2-y, 1-z$. (c) View of 3D network structure of 38 along <i>c</i> axis.	159
Figure 4.17	Cationic structure of 39 with ellipsoids shown at 50% occupancies. Hydrogen atoms and PF ₆ anion in the lattice omitted for clarity.	160
Figure 4.18	Representative FTIR spectra of Ag(I)-NHC complex (41).	164
Figure 4.19	¹ H NMR spectra (<i>d</i> ₆ -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between (a) salt 16 and Ag ₂ O to obtain (b) mononuclear Ag(I)-NHC complex 41 . **DMSO and *H ₂ O.	166
Figure 4.20	¹³ C NMR spectra (<i>d</i> ₆ -DMSO, 125 MHz) indicating the changes in chemical shift of C2 after successful reaction between (a) salt 16 and Ag ₂ O to obtain (b) mononuclear Ag(I)-NHC complex 41 .	167
Figure 4.21	¹ H NMR spectra (<i>d</i> ₆ -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between (a) salt 22 and Ag ₂ O to obtain (b) mononuclear Ag(I)-NHC complex 47 . **DMSO/acetone and *H ₂ O.	170
Figure 4.22	Representative (a) ¹ H NMR and spectra of complex 34 after (a) 15 min and (b) 48 h in 10% aqueous DMSO.	172
Figure 4.23	Representative ¹³ C NMR spectra of complex 36 after (a) 15 min and (b) 48 h in 10% aqueous DMSO.	173

Figure 4.24	(a) Cationic structure of 41 with an ellipsoids shown at 50% probability. Hydrogen atoms and hexafluorophosphate anion have been omitted for clarity. Symmetry element used: $i = 1-x, 2-y, -z$. (b) Interdigitate interactions between binuclear complex in 41 .	175
Figure 4.25	Cationic structure of 43 with thermal ellipsoids shown at 50% probability. Hydrogen atom and molecules in the lattice omitted for clarity. Symmetry elements used: $i = 2-x, 1-y, z$.	176
Figure 4.26	Cationic structure of 44 with thermal ellipsoids shown at 50% probability. Hydrogen atoms and PF_6 anion have been omitted for clarity.	177
Figure 4.27	(a) Cationic structure of 47 with ellipsoids drawn at 50% probability. Hydrogen atoms and PF_6 anion in the lattice were omitted for clarity. (b) The π - π interactions (face-to-face) between benzimidazole ring.	179
Figure 4.28	(a) Cationic structure of 48 with thermal ellipsoids shown at 50% probability. Molecules in the lattice and hydrogen atoms omitted for clarity. (b) The stepped chain section of face-to-face π - π stacking. Symmetry elements used: $i = x-1, y, z$; $ii = 1+x, y, z$.	181
Figure 5.1	Representative FTIR spectrum of Pd(II)-NHC complexes (52).	185
Figure 5.2	Portion of the ^1H NMR spectra (d_6 -DMSO, 500 MHz) indicating the changes in chemical shift after successful reaction between binuclear Ag(I)-NHC complex 48 and $\text{PdCl}_2(\text{COD})$ to give Pd(II)-NHC complex 53 .	187
Figure 5.3	^{13}C NMR spectra (d_6 -DMSO, 125 MHz) indicating the changes in chemical shift after successful reaction between binuclear Ag(I)-NHC complex 48 and $\text{PdCl}_2(\text{COD})$ to give Pd(II)-NHC complex 53 .	188
Figure 5.4	Cationic structure of palladium(II) complex 52 with displacement ellipsoids drawn at 50% probability. Hexafluorophosphate anion has been omitted for clarity.	191
Figure 5.5	Cationic structure of palladium(II) complex 54 (unit A) with displacement ellipsoids drawn at 50% probability. Hexafluorophosphate anion has been omitted for clarity.	194
Figure 5.6	Cationic structure of palladium(II) complex 54 (unit B) with displacement ellipsoids drawn at 50% probability. Hexafluorophosphate anion has been omitted for clarity.	194

Figure 5.7	Cationic structure of palladium(II) complex 55 (unit A) with displacement ellipsoids drawn at 50% probability. Hexafluorophosphate anion has been omitted for clarity.	196
Figure 5.8	Cationic structure of palladium(II) complex 55 (unit B) with displacement ellipsoids drawn at 50% probability. Hexafluorophosphate anion has been omitted for clarity.	196
Figure 6.1	Representative pictures showing zone of inhibition in antibacterial testing of the compounds against <i>E.coli</i> (I) and <i>S. aureus</i> (II) at a concentration of 50 µg/mL.	203
Figure 6.2	Antibacterial activity of test compounds against <i>E. coli</i> .	207
Figure 6.3	Antibacterial activity of test compounds against <i>S. aureus</i> .	207
Figure 6.4	Structures of Ag(I)-NHC complexes with significant activities in the literature.	207
Figure 6.5	Structures of Ag(I)-NHC complexes (29 , 31 and 35) in the present work.	208
Figure 6.6	Representative picture showing minimum inhibitory concentration of the complex 31 activity against <i>E. coli</i> at 12.5 µg/mL. A = AgNO ₃ + bacterial culture, showing turbidity; B = Standard (bacterial culture alone, showing turbidity); C = Complex 31 + bacterial Culture, lacking turbidity.	208
Figure 6.7	Representative picture showing minimum inhibitory concentration of the complexes activity against <i>E. coli</i> at 50 µg/mL. A = 28 + bacterial culture; B = 29 + bacterial culture; C = 32 + bacterial culture; D = Standard (bacterial culture alone, showing turbidity); E = 35 + bacterial culture; F = 37 + bacterial culture; G = 38 + bacterial culture.	208
Figure 6.8	Nuclease activity at 50 µg/mL. M: Marker; C: DNA/RNA alone; Lane 1: DNA/RNA + 28 ; Lane 2: DNA/RNA + 29 ; Lane 3: DNA/RNA + 31 ; Lane 4: DNA/RNA + 32 ; Lane 5: DNA/RNA + 34 ; Lane 6: DNA/RNA + 35 ; Lane 7: DNA/RNA + 37 ; Lane 8: DNA/RNA + 38 .	212
Figure 6.9	Representative pictures showing zone of inhibition in antibacterial testing of the compounds against <i>E. coli</i> (I) and <i>S. aureus</i> (II); A = AgNO ₃ .	213
Figure 6.10	Antibacterial activity of test compounds against <i>E. coli</i> .	215
Figure 6.11	Antibacterial activity of test compounds against <i>S. aureus</i> .	215

Figure 6.12	Structures of (a) first pincer type Ag(I)-NHC complexes used as antimicrobial agents (b) pincer type binuclear Ag(I)-NHC complexes in literature.	216
Figure 6.13	Showing structures of pincer type binuclear Ag(I)-NHC complexes (49 and 50) in the present work.	217
Figure 6.14	Representative pictures showing minimum inhibitory concentration of the compounds activity against <i>E. coli</i> at 12.5 µg/mL. A = complex 50 + bacterial culture, lacking turbidity; B = Standard (bacterial culture alone, showing turbidity); C = AgNO ₃ + bacterial culture, showing turbidity; D = complex 49 + bacterial culture, lacking turbidity.	217
Figure 6.15	Representative picture showing the complexes activity against <i>E. coli</i> at 25 µg/mL. A = 41 + bacterial culture; B = 44 + bacterial culture; C = 50 + bacterial culture; D = Standard (bacterial culture alone, showing turbidity); E = 45 + bacterial culture; F = 47 + bacterial culture; G = 48 + bacterial culture.	217
Figure 6.16	Nuclease activity of selected complexes at 50 µg/mL. M: Marker; C: DNA/RNA alone; Lane 1: DNA/RNA + 41 ; Lane 2: DNA/RNA + 44 ; Lane 3: DNA/RNA + 45 ; Lane 4: DNA/RNA + 46 ; Lane 5: DNA/RNA + 48 ; Lane 6: DNA/RNA + 50 .	220
Figure 6.17	Representative picture showing zone of inhibition in antibacterial testing of the compounds against <i>E.coli</i> . A = AgNO ₃ .	222
Figure 6.18	Antibacterial activity of test compounds against <i>E. coli</i> .	222
Figure 6.19	Antibacterial activity of test compounds against <i>S. aureus</i> .	223
Figure 6.20	Representative picture showing the complexes activity against <i>E.coli</i> at 00 µg/mL. A = 51 + bacterial culture; B = 52 + bacterial culture; C = 53 + bacterial culture; D = Standard (bacterial culture alone, showing turbidity); E = 54 + bacterial culture; F = 55 + bacterial culture.	224
Figure 6.21	Nuclease activity of complexes at 50 µg/mL. M: Marker; Lane 1: DNA/RNA alone; Lane 2: DNA/RNA + 51 ; Lane 3: DNA/RNA + 52 ; Lane 4: DNA/RNA + 53 ; Lane 5: DNA/RNA + 54 ; Lane 6: DNA/RNA + 55 .	226

LIST OF SCHEMES

		Page
Scheme 1.1	Preparation of the First isolated <i>N</i> -Heterocyclic Carbene.	2
Scheme 1.2	Formation of <i>N</i> -heterocyclic carbene-metal complexes by (a) Wanzlick and (b) Öfele.	3
Scheme 1.3	Synthesis of [benz]imidazolium salts by nucleophilic substitution.	6
Scheme 1.4	Synthesis of imidazolium salt by multi-components reaction.	6
Scheme 1.5	Multi-component cyclization and <i>N</i> -alkylation.	7
Scheme 1.6	Primary synthetic routes towards formation of NHC complexes.	8
Scheme 1.7	Synthesis of Ag(I)-NHC <i>via</i> free carbene route.	8
Scheme 1.8	Preparation of metal-NHC complexes by <i>in-situ</i> deprotonation method.	10
Scheme 1.9	NHC transfer of Ag(I)-NHC complexes to Pd(II)-NHC. Complexes.	11
Scheme 1.10	Formation of Pyridine functionalized Pd(II)-NHC complex.	13
Scheme 3.1	Synthesis of [benz]imidazolium salts.	99
Scheme 3.2	A synthetic route to mono-imidazolium salts (1-7).	103
Scheme 3.3	A synthetic route to mono-benzimidazolium salts (8-15).	104
Scheme 3.4	Synthesis of bis-[benz]imidazolium salts (16 – 25).	116
Scheme 4.1	Synthesis of first Ag-NHC complex.	131
Scheme 4.2	Preparation of Ag(I)-NHC complexes by free carbene method.	133
Scheme 4.3	Synthetic methods to prepare Ag(I)-NHC complexes.	133
Scheme 4.4	Synthetic pathway to mononuclear Ag(I)-NHC complexes (26-32).	134
Scheme 4.5	Synthetic pathway to mononuclear Ag(I)-NHC complexes (33, 34, 36 and 37).	135
Scheme 4.6	Synthetic pathway to mononuclear Ag(I)-NHC complexes (35, 38-40).	136

Scheme 4.7	Synthesis of the <i>para</i> -xylyl-linked binuclear Ag(I)-NHC complexes.	162
Scheme 4.8	Synthesis of the pyridine-linked binuclear Ag(I)-NHC complexes.	162
Scheme 4.9	Synthesis of the propyl-linked binuclear Ag(I)-NHC complexes.	163
Scheme 5.1	General synthetic routes to Pd(II)-NHC complex.	183
Scheme 5.2	Synthesis of CNC pincer Pd(II)-NHC complexes 51-55 .	184

LIST OF TABLES

		page
Table 3.1	Important IR data of Mono-[benz]imidazolium salts (1-15).	106
Table 3.2	¹ H NMR (500 MHz) data for the imidazolium salts 1-7 in <i>d</i> ₆ -DMSO.	110
Table 3.3	¹³ C NMR (125 MHz) data for imidazolium salts 1-7 in <i>d</i> ₆ -DMSO.	111
Table 3.4	¹ H NMR (500 MHz) data for the benzimidazolium salts 8-15 in <i>d</i> ₆ -DMSO; (benzimi = benzimidazolium).	112
Table 3.5	¹³ C NMR (125 MHz) data for benzimidazolium salts 8-15 in <i>d</i> ₆ -DMSO.	113
Table 3.6	Important IR data of Bis-[benz]imidazolium salts (16-25).	119
Table 3.7	¹ H NMR (500 MHz) data for the bis-imidazolium salts 16-21 in <i>d</i> ₆ -DMSO.	123
Table 3.8	¹ H NMR (500 MHz) data for the bis-benzimidazolium salts 22-25 in <i>d</i> ₆ -DMSO.	124
Table 3.9	¹³ C NMR (125 MHz) data for the [benz]imidazolium salts 16-25 in <i>d</i> ₆ -DMSO.	125
Table 3.10	Selected bond lengths (Å) and angles (°) for salt 11 .	127
Table 3.11	Selected bond lengths (Å) and angles (°) for salt 16 .	127
Table 3.12	Selected bond lengths (Å) and angles (°) for salt 18 and 23 .	130
Table 4.1	Important IR data of Ag(I)-NHC complexes (26-40).	138
Table 4.2	¹ H and ¹³ C NMR data for imidazolium based mononuclear Ag(I)-NHC complexes 26-32 (500 MHz) in <i>d</i> ₆ -DMSO.	144
Table 4.3	¹ H and ¹³ C NMR data for mononuclear benzimidazolium based Ag(I)-NHC complexes 33-40 (500 MHz) in <i>d</i> ₆ -DMSO.	149
Table 4.4	Selected bond lengths (Å) and angles (°) for 26 .	151
Table 4.5	Selected bond lengths (Å) and angles (°) for 28 .	152
Table 4.6	Selected bond lengths (Å) and angles (°) for 30 .	153

Table 4.7	Selected bond lengths (Å) and angles (°) for 33 and 34 .	155
Table 4.8	Selected bond lengths (Å) and angles (°) for 35 .	156
Table 4.9	Selected bond lengths (Å) and angles (°) for 36 .	157
Table 4.10	Selected bond lengths (Å) and angles (°) for 38 .	160
Table 4.11	Selected bond lengths (Å) and angles (°) for 39 .	161
Table 4.12	Important IR data of Ag(I)-NHC complexes(41-50).	164
Table 4.13	¹ H and ¹³ C NMR data for binuclear imidazolium based Ag(I)-NHC complexes 41-46 (500 MHz) in <i>d</i> ₆ -DMSO.	168
Table 4.14	¹ H and ¹³ C NMR data for binuclear benzimidazolium based Ag(I)-NHC complexes 47-50 (500 MHz) in <i>d</i> ₆ -DMSO.	171
Table 4.15	Selected bond lengths (Å) and angles (°) of 41 .	175
Table 4.16	Selected bond lengths (Å) and bond angles (°) for 43 . ^a	176
Table 4.17	Selected bond lengths (Å) and angles (°) of 44 .	178
Table 4.18	Selected bond lengths (Å) and angles (°) for 47 .	179
Table 4.19	Selected bond lengths (Å) and bond angles (°) for 48 .	181
Table 5.1	Important IR data of Ag(I)-NHC complexes(51-55).	186
Table 5.2	¹ H and ¹³ C NMR data for Pd(II)-NHC complexes 51-50 (500 and 125 MHz) in <i>d</i> ₆ -DMSO.	189
Table 5.3	Selected bond lengths and angles for complex 52 .	192
Table 5.4	Selected bond lengths and angles for complex 54 .	195
Table 5.5	Selected bond lengths and angles for complex 55 .	197
Table 6.1	Antibacterial activities of the compounds ^a against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^b (zone of inhibition ± SD/mm).	205
Table 6.2	Antibacterial activities of the compounds ^a against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^b (zone of inhibition ± SD/mm).	205

Table 6.3	Antibacterial activities of the compounds ^a against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^b (zone of inhibition \pm SD/mm).	206
Table 6.4	Antibacterial activities of the compounds ^a against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^b (zone of inhibition \pm SD/mm).	206
Table 6.5	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>E. coli</i> after addition of constant volume of bacterial solution on a daily basis.	209
Table 6.6	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>E. coli</i> after addition of constant volume of bacterial solution on a daily basis.	209
Table 6.7	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>S. aureus</i> after addition of constant volume of bacterial solution on a daily basis.	210
Table 6.8	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>S. aureus</i> after addition of constant volume of bacterial solution on a daily basis.	210
Table 6.9	Antibacterial activities of the compounds against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^a (zone of inhibition \pm SD/mm).	214
Table 6.10	Antibacterial activities of the compounds against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^a (zone of inhibition \pm SD/mm).	214
Table 6.11	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>E. coli</i> after addition of constant volume of bacterial solution on a daily basis.	218
Table 6.12	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>S. aureus</i> after addition of constant volume of bacterial solution on a daily basis.	219
Table 6.13	Antibacterial activities of the compounds against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^a (zone of inhibition \pm SD/mm).	221
Table 6.14	Antibacterial activities of the compounds against <i>E. coli</i> and <i>S. aureus</i> obtained by the disc diffusion method ^a (zone of inhibition \pm SD/mm).	221

Table 6.15	Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) against <i>E. coli</i> and <i>S. aureus</i> after addition of constant volume of bacterial solution on a daily basis.	224
Table 6.16	Table 6.16: Lipophilicity (Log <i>P</i>) for mononuclear Ag(I)-NHC complexes(26-40)	227
Table 6.17	Table 6.17: Lipophilicity (Log <i>P</i>) for binuclear Ag(I)-NHC complexes(41-50)	227
Table 6.18	Table 6.18: Lipophilicity (Log <i>P</i>) Pd(II)-NHC complexes(51-55)	228

LIST OF ABBREVIATIONS

NHC	<i>N</i> -heterocyclic carbene
[Benz]imidazole	Imidazole and benzimidazole
Benzimi	Benzimidazolium
Ar	Arene
Aliph	Aliphatic
DMF	<i>N,N</i> -dimethylformamide
DMSO	Dimethylsulfoxide
DCM	Dichloromethane
THF	Tetrahydrofuran
NaH	Sodium hydride
h	Hour
MIC	Minimum inhibitory concentration
5FU	5-Fluorouracil
Anal.	Analysis
Calc.	Calculated
<i>J</i>	Nuclear spin-spin coupling constant through bonds
Å	Angstrom
<i>h</i>	Crystallographic index
α	Crystallographic unit-cell angle between axes <i>b</i> and <i>c</i>
β	Crystallographic unit-cell angle between axes <i>a</i> and <i>c</i>
<i>a</i>	Crystallographic unit cell axis <i>a</i>
<i>b</i>	Crystallographic unit cell axis <i>b</i>
<i>c</i>	Crystallographic unit cell axis <i>c</i>

NaOAc	Sodium acetate
Et ₃ N	Triethyl amine
<i>t</i> -BuOk	Potassium tertiary butoxide
COD	1,5-Cyclooctadiene
KHMDS	Potassium hexamethyldisilazide
NMR	Nuclear magnetic resonance spectroscopy
XRD	X-ray diffraction
OD	Optical density
ORTEP	Oak Ridge Thermal Ellipsoid Plot
Mes	Mesityl

LIST OF PUBLICATION AND CONFERENCES

International journals

Asekunowo, P.O., Haque, R.A., Razali, M.R., Budagumpi, S. (2015). Benzimidazole-based silver(I)-*N*-heterocyclic carbene complexes as antibacterials: synthesis, crystal structures and nucleic acids interaction studies. *Applied Organometallic Chemistry*, 29: 126-137.

Asekunowo, P.O., Haque, R.A., Razali, M.R., Budagumpi, S. (2015). Sterically modulated silver(I) complexes of *N*-benzyl substituted *N*-heterocyclic carbenes: synthesis, crystal structures and bioactivity. *Transition Metal Chemistry*, 40:79–88.

Asekunowo, P. O., Haque, R.A (2014). Counterion-induced modulation in biochemical properties of nitrile functionalized silver(I)-*N*-heterocyclic carbene complexes. *Journal of Coordination Chemistry*, 67: 3649-3663.

Haque, R. A., **Asekunowo, P. O.**, & Budagumpi, S. (2014). Binuclear silver (I) complexes of *p*-xylyl/2, 6-lutidinyl linked bis-*N*-heterocyclic carbene ligands: Synthesis, crystal structures and biological evaluation. *Inorganic Chemistry Communications*, 47: 56-59.

Haque, R. A., **Asekunowo, P. O.**, Razali, M. R. (2014). Synthesis and crystal structures of sterically tuned ether functionalized NHC-silver (I) complexes; Antibacterial and nucleic acid interaction studies. *Journal of Coordination Chemistry*, 67: 2131-2147.

Haque, R. A., **Asekunowo, P. O.**, Razali, M., & Mohamad, F. (2014). NHC–Silver(I) Complexes as Chemical Nucleases; Synthesis, Crystal Structures, and Antibacterial Studies. *Heteroatom Chemistry*, 25: 194-204.

Haque, R. A., **Asekunowo, P. O.**, Razali, M. R. (2014). Dinuclear silver (I)-N-heterocyclic carbene complexes of N-allyl substituted (benz)imidazol-2-ylidenes with pyridine spacers: synthesis, crystal structures, nuclease and antibacterial studies. *Transition Metal Chemistry*, 39: 281-290.

Haque, R. A., Iqbal, M. A., **Asekunowo, P.**, Majid, A. A., Ahamed, M. B. K., Umar, M. I., Al-Suede, F. S. R. (2013). Synthesis, structure, anticancer, and antioxidant activity of *para*-xylyl linked bis-benzimidazolium salts and respective dinuclear Ag (I) N-heterocyclic carbene complexes (Part-II). *Medicinal Chemistry Research*, 22: 4663-4676.

Conference

Patrick O. Asekunowo and Rosenani A. Haque (2013). Functionalized Pincer Type N-Heterocyclic Carbene Ligands. 4th International Conference for Young Chemists (ICYC), 30 January-1 February, Bayview Hotel, Penang, Malaysia.

Workshops

Participated in “The Art of Writing Publishable Scientific Manuscript and Beyond” Penang, 26th February, 2013.

Attended occupational Safety and Health Course; Universiti Sains Malaysia. Penang, Malaysia, February 2013.

**SINTESIS, STRUKTUR DAN CIRI ANTIMIKROB KOMPLEKS
ARGENTUM(I)- DAN PALLADIUM(II)-N-HETEROSIKLIK KARBENA
BARU TERBITAN [BENZ]IMIDAZOL-2-ILIDENA**

ABSTRAK

Tesis ini melaporkan sintesis, struktur dan ciri antimikrob pelbagai kompleks argentum (I)- dan palladium(II)-NHC mengandungi ligan [benz]imidazolin-2-ilidena. Hasil penemuan penyelidikan ini dibentangkan dalam empat bab. Dua jenis garam [benz]imidazolium dengan gantian yang berlainan telah disediakan. Jenis yang pertama ialah garam mono-[benz]imidazolium (**1-15**) yang berteraskan eter, nitril dan alil. Kesemua garam mudah diubah dengan menggunakan gantian akil/akil aril pada posisi ketiga pada gelang [benz]imidazolium. Manakala jenis yang kedua ialah garam bis-[benz]imidazolium (**16-25**) terbitan sistem terangkai propil, piridina dan para-xilena. Kompleks disediakan melalui tindakbalas *in situ* Ag₂O dengan garam [benz]imidazolium sepadan secara mempelbagaikan nisbah molar logam kepada garam, menghasilkan dua puluh lima kompleks Ag(I)-NHC (**26-50**) yang baru. Struktur kristal sinaran-X bagi lima belas kompleks telah ditentukan dan menunjukkan variasi dalam corak struktur merentangi siri dengan spesies mononuklear dan dinuklear. Garam dan kompleks telah dicirikan dengan kaedah spektroskopi (FTIR, ¹H dan ¹³C NMR), analisis unsur (CHN) dan kaedah pembelauan sinaran-X kristal tunggal. Kesan daripada gantian yang berbeza pada kompleks ke atas aktiviti antibakteria telah diuji. Efikasi antibakteria bagi sebatian telah diperiksa dengan menggunakan *Staphylococcus aureus* (ATCC 12600) sebagai bakteria Gram positif dan *Escherichia coli* (ATCC 25922) sebagai bakteria Gram negatif. Kesemua kompleks Ag(I)-NHC, secara umumnya, menunjukkan aktiviti antibakteria yang baik dengan nilai dalam lingkungan 10.0±0.5-32.9±2 mm untuk zon perencatan tumbuhan bakteria dan nilai MIC untuk kompleks adalah dalam

lingkungan 6.25-100 $\mu\text{g}/\text{mL}$. Walau bagaimanapun, garam berkaitan adalah tidak aktif pada dasarnya bagi kedua-dua strain bakteria. Adalah diperhatikan bahawa terbitan kompleks Ag(I)-NHC dengan rantaian alkil yang lebih panjang bersifat lebih bioaktif. Seterusnya keputusan juga menyokong bahawa kompleks Ag(I)-NHC dinuklear mempunyai potensi antibakteria yang lebih baik daripada seiring mononuklear mereka. Untuk memperolehi pandangan tempoh awal pada mod tindakan sebenar mereka, plasmid pекeliling pTS414 DNA/RNA telah didedahkan pada gel elektroforesis dan didapati Ag(I)-NHC mononuklear (**31**, **34**, **37**, dan **38**) dan Ag(I)-NHC dinuklear (**41**, **44**, **45**, **46** dan **48**) adalah sangat efisien dalam menggalakkan rekahan/degradasi RNA dan DNA tanpa kehadiran zat tindakbalas iaitu dalam ketidakhadiran H_2O_2 dan reduktan tambahan.

Sintesis CNC bersepadu kompleks Pd(II)-NHC telah dicapai melalui tindakbalas pentranslogaman (pemindahan NHC) antara Pd(cod)Cl₂ dengan kompleks Ag(I)-NHC terbitan garam bis-[benz]imidazolium yang berkenaan. Kajian sinaran-X menunjukkan struktur mononuklear untuk tiga kompleks (**52**, **54** dan **55**) dalam keadaan pepejal. Kompleks Pd(II)-NHC yang disediakan telah diuji dengan *E. coli* dan *S. aureus*. Kompleks yang diuji menunjukkan aktiviti pada bakteria yang disebut, tetapi lebih rendah dibandingkan dengan kompleks Ag(I)-NHC. Keputusan daripada aktiviti nuklease tempoh awal menunjukkan kompleks Pd(II)-NHC (**51**, **52**, **54** and **55**) adalah efisien dalam rekahan asid nukleik melalui mekanisme tak teroksidasi.

SYNTHESIS, STRUCTURE AND ANTIMICROBIAL PROPERTIES OF NEW SILVER(I)- AND PALLADIUM(II)-N-HETEROCYCLIC CARBENE COMPLEXES DERIVED FROM [BENZ]IMIDAZOL-2-YLIDENES

ABSTRACT

This thesis reports the synthesis, structure and antimicrobial properties of various silver(I)- and palladium(II)-NHC complexes bearing [benz]imidazolin-2-ylidene ligands. The findings of the research are presented in four chapters. Two types of [benz]imidazolium salts with different substituents were prepared. The first type is mono-[benz]imidazolium salts (**1-15**) with ether, nitrile and allyl functionalities. They are conveniently tuned, using different alkyl/alkyl aryl substituents at the 3-position of the [benz]imidazolium ring. While the second type is bis-[benz]imidazolium salts (**16-25**) derived from propyl, pyridine and para-xylene linked systems. The complexes were prepared by *in situ* reaction of Ag₂O with the corresponding [benz]imidazolium salts by varying the metal to salt molar ratio, resulting in the isolation of twenty five new Ag(I)-NHC complexes (**26-50**). X-ray crystal structures for fifteen of these complexes were determined showing a variation in the structural motifs across the series with mononuclear and binuclear species being generated. The salts and their complexes were characterized by spectroscopic methods (FTIR, ¹H and ¹³C NMR), elemental analysis (CHN) and single crystal X-ray diffraction techniques. The effect of substitutions on antibacterial activity of these compounds has been investigated. Compounds were screened for their antibacterial efficacy against *Staphylococcus aureus* (ATCC 12600) as a Gram positive bacterium and *Escherichia coli* (ATCC 25922) as a Gram negative bacterium. All the Ag(I)-NHC complexes, in general, showed good antibacterial activities in the range 10.0±0.5-32.9±2 mm for the zone of bacterial growth inhibition and the MIC values of the complexes are in the range of 6.25-100 µg/ mL.

However, their corresponding salts were essentially inactive against both strains of bacteria. It was observed that the derivatives of the Ag(I)-NHC complexes with longer alkyl chain were more bioactive. Furthermore the results also suggest that binuclear Ag(I)-NHC complexes have relatively better antibacterial potential compared with their mononuclear counterparts. In order to gain preliminary insights into their actual mode of action(s), circular plasmid pTS414 DNA/RNA was exposed to gel electrophoresis and it was found that the mononuclear Ag(I)-NHC (**31**, **34**, **37** and **38**) and binuclear Ag(I)-NHC (**41**, **44**, **45**, **46** and **48**) are extremely efficient in promoting the cleavage/degradation of RNA and DNA in the absence of co-reactants i.e., in the absence of H₂O₂ and added reductant.

The synthesis of CNC pincer Pd(II)-NHC complexes has been achieved by the transmetallation (NHC transfer) reaction between Pd(cod)Cl₂ and the corresponding Ag(I)-NHC complexes derived from bis-[benz]imidazolium salts. X-ray studies revealed mononuclear structures for three of the complexes (**52**, **54** and **55**) in solid state. The prepared Pd(II)-NHC complexes were tested against the *E. coli* and *S. aureus*. The examined complexes showed an activity against the mentioned bacteria, but much lower than that of the Ag(I)-NHC complexes. The results of the preliminary nuclease activities demonstrate that Pd(II)-NHC (**51**, **52**, **54** and **55**) complexes are efficient in the cleavage of nucleic acids *via* non-oxidative mechanism.

CHAPTER ONE

INTRODUCTION

1.1 *N*-Heterocyclic Carbenes (NHCs)

NHCs are electron rich σ -donor ligands with zero formal charge on the carbene carbon.¹ Generally, NHCs possess the carbene carbon located at the 2-position between the two nitrogen substituents (Figure 1.1 a). They are singlet carbenes which are electronically and sterically stabilized. It is the inductive (-I) and the mesomeric (+M) push-pull effect that provides most of the stabilizing energy.^{2,3,4} However, by changing the type of azole ring electronic properties can be adapted with the following order of electron donating power benzimidazole < imidazole < imidazoline (Figure 1.1 b).⁵

NHCs have been found as efficient substitutes to phosphine ligands due to many advantages as ancillary ligands.⁶ The availability of sterically impeded functional group attached to the nitrogen atoms promotes reductive elimination of the product from the metal. The influence of the metal-carbene bond of the NHC complex facilitates ligand dissociation and they are also better σ -donors than phosphine ligands. Lastly the carbene carbon containing the unfilled orbitals is normally part of the heterocycle (azole ring system), therefore the properties of the NHCs can be finely tuned by the addition of electron donating substituents on the nitrogen atoms, affording them exceptional coordinating power and superior multidentate ligands.^{7,8}





Figure 1.1: (a) Position of the carbene carbon (b) Order of electron donating power.


1.2 Background

Carbenes have been known as an exclusive type of intermediate, as far back as 1954 according to the earlier work by Doering.⁹ After the introduction of carbenes by Doering to organic chemistry⁹ and ten years later by Fischer and Maasbol to organometallic chemistry,¹⁰ they have attracted the interest of synthetic¹¹ and organometallic¹² chemists exceedingly. However it was not until Arduengo isolated and characterised the first stable NHC in 1991 (Scheme 1.1)¹³ that the interest of the scientific community was revived.¹⁴⁻¹⁶ This discovery led to the use of NHC in the development of carbene system. After this, different methods for the isolation of heterocyclic carbenes have been reported by a number of research groups.^{17,18,19,20}



Scheme 1.1: Preparation of the first isolated NHC.

NHCs have been known due to earlier work done in 1968 by Wanzlick and Ofele who were able to use them to form mercury-salt and chromate carbene complexes.^{21,22} The mercury complex was formed from the metal acetate, while Ofele used carbonyl metalate for the chromate complex (Scheme 1.2). The carbenes intermediate were claimed to have been prepared by *in situ* technique from corresponding imidazolium salts.²²



Scheme 1.2: Formation of NHC-metal complexes by (a) Wanzlick and (b) Öfele.²²

1.3 Structural diversities and stability

NHCs possess several variations in their basic structures (Figure 1.2). Examples of these are imidazol-2-ylidene **I**, imidazolidin-2-ylidene **II**, a five-membered 1, 2, 4-triazolin-(3, 5)-ylidene **IV** with the presence of carbenes at the 3 and 5-positions, thereby enhancing the possibility of binding to one or more metal centres.²³ Furthermore there is six membered tetrahydropyrimid-2-ylidene **V**²⁴ and several other heterocyclic carbenes have already been reported, such as four-

membered rings,²⁵ 1, 3-thiazole²⁶, cyclic alkyl(amino)carbenes,^{27,28} P-heterocyclic carbenes (PHCs).^{29,30} However five membered NHCs are the most broadly studied³¹.




Figure 1.2: Types of NHC ligands.

The contributions of the 6 π -electrons in unsaturated NHCs to the stability of the carbene centre have been a disputable contention.^{28,32} NHCs of this type are proposed to stabilize the singlet state when there are unshared electrons paired in the same σ or π orbitals as a result of the inductive (-I) and the mesomeric (+M) push-pull effect (Figure 1.3).³² Thus the negative inductive effect of the nitrogen on the carbene carbon decreases the energy of σ non-bonding orbital by increasing its s-character and leaving the $P\pi$ orbital unaltered, thereby favouring the singlet state.¹⁶ The mesomeric effect occurs when the carbon orbitals (s, $p\pi$ or p_x , p_y) interact with the p or π orbitals of the nitrogen substituents. The substituents lone pair improves the $P\pi$ character of the singlet carbenes *via* electron transfer to the vacant $P\pi$ orbitals of the carbenes.¹⁶

Dixon and Arduengo formerly stated that the stability of NHCs was mainly as a result of the inductive charge transfer from the carbene carbon to the nitrogen substituents, and that the mesomeric effect is quite insignificant.^{28,33} It was also proposed that the double bond unsaturation would facilitate a delocalisation of

electron density around the ring, thereby providing a small but valid contribution to the overall stability of the NHC.^{16,35-37}




Figure 1.3: Electronic stabilisation of NHCs.


This was considered to have justified Arduengo's isolation of a free carbene with an unsaturated backbone, while Wanzlick's earlier work on saturated systems produced dimers.³⁸ However in 1995, NHC bearing saturated backbone was isolated and it became clear that the contribution of delocalisation could only give little stabilisation.¹⁸ and that mesomeric π -electron donation from the nitrogen atoms to the carbene centre is adequate for the stabilisation of the free carbene.³⁵

1.4 Synthesis of azolium salts: the NHC precursors

NHC precursors are prepared by two common pathways:³⁹

1.4.1 Nucleophilic substitution


This route involves step-by-step alkylation of azole (imidazole, benzimidazole, triazole etc) in the presence of strong base such as KOH and NaOH. The potassium or sodium azolide formed is then treated with one equivalent of alkyl or aryl halide in a suitable solvent to obtain *N*-alkyl/aryl substituted azole.⁴⁰ The *N*-substituted azole is subsequently reacted with one equivalent of appropriate alkyl/aryl halide to yield disubstituted derivatives of imidazolium salts (Scheme 1.3).



Scheme 1.3: Synthesis of [benz]imidazolium salts by nucleophilic substitution.⁴⁰


1.4.2 Multi components one step reaction

This route involves one pot synthesis, starting from glyoxal, primary amine and formaldehyde leading to the desired products. The reaction proceeds through a coupling between amine and glyoxal and forms the corresponding Schiff base. Condensation with formaldehyde leads to the imidazolium salt. The multicomponent reaction of primary amines, glyoxal, and formaldehyde in the presence of a Brønsted acid has been developed for the introduction of reactive *N*, *N'*-substituents (Scheme 1.4).⁴¹



Scheme 1.4: Synthesis of imidazolium salt by multi-components reaction.⁴¹

This flexible reaction gives access to a multitude of symmetrically *N*, *N'*-substituted imidazolium salts. Unsymmetrical substituted azolium salts can also be prepared by the combination of a multicomponent cyclization with an *N*-alkylation reaction. The initial cyclization gives an *N*-alkyl imidazolium salt, which is then alkylated at the second nitrogen atom to obtain the asymmetrically substituted derivative (Scheme 1.5).⁴²




Scheme 1.5: Multi-component cyclization and *N*-alkylation.⁴²

1.5 Preparation of NHC complexes


NHCs have been extensively used due to their favourable properties over phosphine and its strong coordination with main group and transition metals. Recently, researchers have adopted a number of synthetic procedures to prepare NHC complexes of d-block and main group metals.^{43,44} The outline of the main synthetic methods is presented in Scheme 1.6.

(a) Free Carbene Route

This method was achieved by the reaction of suitable metal compounds with free NHCs. The deprotonation of the azolium salt results in the free NHC generation and the subsequent reaction with an appropriate metal compound to yield the transition metal carbene complex (Scheme 1.7).^{45,46,47} Free carbene route has been adopted in the preparation of vast array of metal complexes but the choice of this procedure is constrained due to the conditions needed to afford the free carbene. Strong bases such as KH or KO^tBu are often used and usually they can result in the deprotonation of some other acidic protons in the ligand. Therefore this method is limited to imidazolidin-2-ylidenes and benzimidazolin-2-ylidenes because the deprotonation can give rise to decomposition, especially in ligands where the methylene groups are in the α position of the nitrogen atoms of the NHC.⁴⁸⁻⁵⁰



Scheme 1.6: Primary synthetic routes towards formation of NHC complexes.⁴³




Scheme 1.7: Synthesis of Ag(I)-NHC *via* free carbene route.⁴⁵

(b) *In situ* deprotonation of azolium salts

This method is based on the deprotonation of azolium salts by the use of external bases such as sodium acetate,⁵² triethylamine,⁵³ NaH, *t*-BuOLi or *t*-BuOk,^{14,51} and other bases have also been reported, such as silver oxide (Scheme 1.8)⁵⁴⁻⁵⁷ and palladium acetate (Scheme 1.8).⁵⁸ The first NHC complexes reported by Wanzlick and Öfele have been prepared by this method.^{21,53} This method is remarkably favourable, considering the fact that air and moisture sensitive free carbenes can be by-passed. Most of the complexes of NHCs discussed in this work were prepared using this method.

(c) Transmetallation (NHC transfer reaction):


Lin and co-workers were the first to report this method in 1998.⁵⁴ In this method, Ag₂O was used as the basic metal source for the deprotonation of the azolium salts to give Ag-NHC complexes. This method has been successfully used with a variety of metals such as Rh, Ir, Pd, Pt, Ru, Cu and Au.^{59,60} As a result of their lability, Ag(I)-NHC complexes are easily used as NHC transfer agents in the preparation of Pd (II) (Scheme 1.9), Au (I), Rh(I) and Ir(II) NHC complexes. This procedure has been extensively used due to the moderate reaction conditions, leading to the formation of more stable products. The absence of ^{107,109}Ag-¹³C coupling in the ¹³C NMR and the labile nature of the Ag-NHC complexes was suggested to be one the reasons for the easy NHC transfer.⁵⁴ The procedure is such that, a suitable azolium salt was treated with Ag₂O, AgCO₃ and AgOAc to obtain Ag(I)-NHC complexes. Thereafter, the obtained Ag(I)-NHC complexes were made to react with the other metal sources to give the proposed metal-NHC complexes.⁶¹



Scheme 1.8: Preparation of metal-NHC complexes by *in-situ* deprotonation method.⁵⁸

The synthesis of Pd(II)–NHCs other than transmetallation method, such as direct metalation of azolium salt with Pd(OAc)₂ or with Pd(II)-precursor in the presence of external base were also investigated. The work by Gade and co-workers,⁶² Tilstet and co-workers,⁶³ Cavell and co-workers⁶⁴ and Shreev and co-workers⁶⁵ pointed out the inefficacy of direct metalation to prepare Pd(II)–NHCs. Consequently, transmetallation by Ag(I)–NHCs became a general interest. However, there are some shortcomings that were reported in using the transmetallation method. Hahn and co-workers,⁶⁶ Bildstein and co-workers,⁶⁷ Magil and co-workers⁶⁸ reported the low yield and non-success of transmetallation. Mata and co-workers also reported unsuccessful formation of a chelate complex with the intended metal-NHC complex.⁶⁹ These failures were proposed to have been caused by the presence of a

strong C_{carbene}-Ag bond. The Pd(II)-NHC complexes discussed in present work were obtained by this route.



Scheme 1.9: NHC transfer from Ag(I) centre to Pd(II) centre.⁵⁴

1.6 Functionalized NHC complexes

Research on functionalised NHC complexes has developed rapidly over the last few years.⁷⁰⁻⁷⁴ The formation of NHC complexes by reacting NHC precursor with a number of donors in the ligand framework gives innovative coordination chemistry.⁷⁴ Functionalized NHCs with excellent donor groups of nitrogen and oxygen are exclusively diverse in number. In this work, the synthesis and structural characterisation of NHC complexes functionalized with oxygen and nitrogen donor groups are highlighted as important part of the present study.

1.6.1 Functionalized NHCs and metal complexes containing nitrogen donors

The modelling of functionalized NHCs with nitrogen donor groups is given a considerable attention much more than phosphine donor groups. Especially, the inclusion of pyridine functionality into polydentate ligand framework of NHCs is of great significance. This high interest in pyridine functionality could be partially due to the simple synthetic procedure associated with the ligand precursors and the interesting rigidity transmitted to the metal complexes from the chelate rings and addition to the exceptionally thermal stability.⁷² Pincer-type ligands based on pyridine–dicarbene have gained considerable attention as a result of the increased stability and a strengthened rigidity (Figure 1.4). Furthermore, NHC with a central imidazole ring and two flanking pyridine side-arms have been studied by several research groups.^{68,75–78} The ligand precursor (**VII**) forms Pd (II) complex (**VIII**) due to the small bite angle resulting in the bidentate coordination of the two ligands (Scheme 1.10).⁷⁵ Complex (**VIII**) shows a fluxional behaviour in solution because of the hemilabile characteristic of the ligand with the coordinated and free pyridine arms.⁷⁵





Figure 1.4: Pyridine NHC ligands.



Scheme 1.10: Formation of Pyridine functionalized Pd(II)-NHC complex.⁷⁵

Apart from pyridine functionality, other varieties of functionalized NHCs with nitrogen donor groups, like imine, amide, nitrile, oxazoline, pyrazole, and amine are also well-known.^{79,80} The first amide functionalised NHC (**IX**) was reported by Arnold et al. and was prepared in good yield by the alkylation of *tert*-butyl imidazole with *t*-BuNHCH₂CH₂Br.HBr.⁸¹ Fryzuk et al. was able to establish the first models of tridentate bis-amine NHC precursor (**X**). In 2009 Wylie et al. reported the synthesis of unsymmetrical nitrile functionalized NHC precursor (**XI**) from 2-cyanophenylimidazole (Figure 1.5). The reactions of these novel imidazolium salt with Ag₂O yielded novel Ag(I)-NHC complex (**XII**).⁸² Although an analogous nitrile-functionalized NHC complex of Pd(II) (**XIII**) was reported earlier by Dyson and co-workers.⁸³ See Figure 1.6 below.






Figure 1.5: Examples of N-functionalized NHC precursors.



XII



XIII

Figure 1.6: Examples of N-functionalized Ag(I)-NHC and Pd(II)-NHC complexes.

1.6.2 Functionalized NHCs and metal complexes containing oxygen donors

Functionalized NHCs bearing oxygen donors, like ester,^{84,85} ether,^{73,86,87} hydroxyalkyl^{88, 89} and ketone components^{85,90} have been reported. In most cases for the complexes, the oxygen functionalities of these NHC precursors are not coordinated^{84,86,89,90} (Figure 1.7) but complexes with the chelated oxygen functionalities are also known.^{90,91} Früstner et al. showed that ester functionality can also be connected with the NHC moiety.⁸⁴ Takacs et al. also reported the preparation of acylfunctionalized NHC precursor⁸⁸ and was found as an efficient Pd-catalyzed Suzuki-Miyaura coupling reactions. According to cited literatures above, it is worthy of note to mention that most of the research on functionalized complexes have been directed towards catalysis. So far research involving functionalized NHC complexes for biological studies is quite rare.




Figure 1.7: Examples of O-functionalised Ag(I)-NHC and Pd(II)-NHC complexes.

1.7 Antibiotics

Antibacterial agents, or antibiotics, are a class of a larger group of compounds called antimicrobial agents. Earlier, antibiotics were referred to as only naturally occurring molecules produced by a variety of microorganisms.⁹² However, the term has transformed to include man-made synthetic compounds.⁹³ Antibiotics can be categorised into four distinct classes based upon their mechanism of action. Those four classes are (1) the agents that inhibit bacterial cell wall biosynthesis, (2) the agents that inhibit protein biosynthesis, (3) the agents that inhibit deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) synthesis, and (4) the agents that inhibit folate synthesis.⁹³

Inhibitors of Bacterial Cell Wall Biosynthesis:

β -lactam antibiotics act on diverse targets within the biosynthetic cascade of cell wall formation. This family of compounds is comprised of four groups of

molecules: (1) the penicillins, (2) the cephalosporins, (3) the carbapenems, and (4) the monobactams. They all act *via* the same mechanism of action, and that is by binding and inhibiting the penicillin binding proteins (PBPs); more specifically they inhibit peptidoglycan transpeptidase causing lysis and cell death.⁹³

Inhibitors of Protein Biosynthesis:

This class of compounds exert their antibacterial action by blocking one or more of the steps in protein biosynthesis that occur on either the 30S or 50S subunits of the bacterial ribosome. There are a number of families of molecules that make up this family including the macrolides, lincosamides, streptogramins, oxazolidinones, aminoglycosides, and tetracyclines.⁹³ However, the major families that compose this family are the aminoglycosides, macrolides, and tetracyclines. These antibiotics show potent activity against gram-negative bacteria, but lack potent activity against most gram-positive bacteria. However, they are used in combination with β -lactams to treat some enterococcal infections.⁹³

Inhibitors of DNA and RNA Synthesis:

This class of antibiotics works on one of three targets: DNA gyrase, topoisomerase IV, or DNA-directed RNA polymerase. There are two families of antibiotics included within this class, and those are the quinolones and the rifamycins. The activity of the quinolones is derived from their inhibition of DNA gyrase and topoisomerase IV.⁹² While DNA gyrase and topoisomerase IV have similar mechanisms of action, the difference is the fact that DNA gyrase is more important for gram-negative organisms and topoisomerase IV is more important for gram-positive organisms.⁹⁴ The quinolones work by binding to DNA gyrase or topoisomerase IV and preventing the supercoiling of DNA, thereby inhibiting synthesis of DNA.⁹³ The quinolones were not widely used until the discovery of the

fluoroquinolones in the 1980s.⁹⁵ There are presently four generations of quinolones that have been developed and are in clinical use. The rifamycin family of antibiotics works on DNA-directed RNA polymerase. These agents bind to the β -subunit of DNA-directed RNA polymerase and inhibit the initiation of chain formation in RNA synthesis.⁹³ Rifamycin is a natural product with several natural analogs, but three semisynthetic analogs have since been synthesized. Those agents are rifampin, rifabutin, and rifapentine. These agents are front-line agents in the treatment of tuberculosis.⁹³

Inhibitors of Folate Synthesis:

Folate is very important to the survival of all living organisms.⁹⁶ It plays a considerable role in DNA synthesis by serving in the transfer of methyl, formyl, and other single-carbon fragments in the biosynthesis of purine nucleotides.⁹⁷ Humans and bacteria obtain folate via different routes. Humans obtain folate through their diet, while bacteria synthesize folate through the folate biosynthetic pathway. This difference makes the folate biosynthetic pathway a very attractive drug target.⁹⁶ There are two enzymes in this pathway that are currently targeted by antibacterial agents: dihydropteroate synthesis (DHPS) and dihydrofolate reductase (DHFR). The family of agents that act on DHPS is the sulfonamides. DHFR is acted upon by a single agent, and that is trimethoprim.⁹² The sulfonamides work by inhibiting DHPS, which catalyses the conversion of *p*-aminobenzoic acid (PABA) to dihydropteroate.^{98,99} As a result of resistance issues, most of the originally developed sulfonamide drugs are no longer in use as a monotherapy. However, some are still in use for acne and urinary tract infections. The most commonly used drug in this class is sulfamethoxazole. This agent is often used in combination with trimethoprim,

which expands its antibacterial spectrum and reduces the potential for the development of drug resistance.⁹⁴

1.8 Biological applications of Ag(I) and Pd(II)-NHC complexes

1.8.1 Background

Penicillin resistant *staphylococcus aureus* (*S. aureus*) strains were first reported in the 1940s. However, research on anti-microbial is considered to have started in 1928 with the accidental discovery of penicillin by *Alexander Fleming*.¹⁰⁰ Anti-bacterial drug discovery reached its apex in the 1950's and of the majority of these compound classes are still in use today.¹⁰¹ In 1959 methicillin was introduced but again *S. aureus* quickly developed resistance which was later referred to as Methicillin-resistant *S. aureus* (MRSA).^{101,102} Resistance by MRSA's were also reported in the earlier years of the 1980's against such antibiotics like erythromycin, neomycin, gentamycin and ciprofloxacin in 1990's.¹⁰³ After the introduction of streptogramins and quinolones earlier in the 1960's, no novel class of anti-bacterial agent was introduced into clinical practice until linezolid was launched in 2000. Considering the diversity of bacterial structures, drug discovery in this area requires agents with specific biomolecular targets or routes. Bacterial microorganisms have utilized anti-bacterial xenobiotics to develop a complex arsenal of defences to protect themselves from attack. Consequently, some researchers suggest the superior role of natural products, owing to evolutionary conditions, in producing an array of antibiotic producing microorganism, compared with synthetic libraries.¹⁰² However, these antibiotics function by targeting specific biomolecular pathways and as a result have a propensity for the development of resistance to prophylactic treatment.

Later in 2002, it was reported that Vancomycin-resistant *S. aureus* (VRSA) was identified and isolated.^{104,105} Bacteria can develop resistance surprisingly fast,

arising through either an alteration of the target site or enzyme, inhibition of the antibiotics to gain access and destruction or deactivation of the antibiotics.¹⁰⁶ Therefore highly resistant pathogenic bacteria causing life threatening infectious diseases are appearing, especially, strains which are no more responding to treatment by any possible antibiotics. A number of studies have been carried out on the effect of bacterial infections, one example of such is the effect of *S. aureus* peritoneal infection on a mouse model, the studied revealed the presence of intraperitoneal abscesses in the vicinity of inoculation sites, a disease that occurs frequently in humans undergoing continuous ambulatory peritoneal dialysis for end-stage renal disease (Figure 1.8).¹⁰⁷

During the last two decades, numerous anti-bacterial agents have been developed and offered into the market, however their effectiveness has over the years deteriorated and failed to solve the problem of multidrug resistant bacteria.¹⁰⁸⁻¹¹⁰ Therefore, there is a need to develop novel anti-microbial compounds with an entirely different mechanism in order to curb the fatality of multidrug-resistant bacteria. In the light of this, organometallic derivatization was proposed as an attractive approach to subdue the resistance problem. This approach could possibly provide a metal mode of action which is specific and non-existence for the purely organic parent drug molecule.¹¹¹⁻¹¹⁴ In certain conditions, it was suggested that the effectiveness of a metal-based-drug could be as a result of the original activity and the inherent toxicity of the inorganic metal.¹¹⁴ It has already been established that the potentiality of bacteria to cultivate resistance against silver-based anti-microbials is constrained, therefore affording such antibiotics to possess a long shelf life.^{115,116} The development of metal-containing anti-cancer and anti-malarial compounds has shown a lot of advancement.¹¹⁷⁻¹²² However, very little awareness has been shown

for the development of organometallic anti-bacterial drugs. Therefore, research on metal-based anti-bacterial compounds is very appropriate and desirable.

To date a large number of studies have been carried out on Ag(I) complexes as potential anti-microbials, anti-cancer and their carbene transfer ability.¹²³⁻¹²⁶ Also Ag(I)-complexes have shown interesting DNA binding ability,¹²⁷⁻¹²⁹ however there is paucity of data on their ability to cleave the nucleic acids (DNA/RNA). On the other hand, the interaction of Ag(I)-NHC complexes with nucleic acids is a significant field of research to be explored to a greater extent due to the utility of these carbene complexes in the development of spectroscopic probes, diagnostic agents and site-specific nucleic acid cleavers, among others.¹³⁰ It is worthy of mentioning that apart from DNA there are some other biological targets including RNA, enzyme or protein. Therefore it is considered worthwhile to investigate the interaction of these synthesized compounds with DNA and/or RNA as an initial experiment to study the likely mode of action(s) of the reported compounds.




Figure 1.8: Staphylococcal lesions associated with the kidney.¹⁰⁷

1.8.2 Biological applications of Ag(I)-NHC complexes

Biological studies of Ag(I)-NHC complexes are established on the knowledge that elemental silver and its salts have long been recognized for their potential in the protection of the eyes of newborns from infection, as well as their anti-microbial properties, essentially against chronic ulcers, extensive burns, and wounds.^{131,132} This astounding activity of silver or Ag(I)-NHC complexes against bacteria, fungi, and yeast is due to slow delivery of silver cations across the cell membrane, which mostly interferes with the electron transport system of the cell and also interacts with the thiol groups of the vital enzymes of bacteria.¹³³ Ag(I)-NHC complexes offers encouraging results to overcome the problems of drug resistance of some pathogenic bacteria, which has so far eluded the effectiveness of sulphonamides. Recently, Ag(I)-NHC/coordination complexes have been found to display potential anti-microbial activity, particularly for the potential treatment of cystic fibrosis and chronic lung infections,^{134,135} which makes them appropriate entities for drug development.¹³⁶ The enhanced stability of the complexes is anticipated to be useful for anti-microbial activity, because silver is released gradually as compared to ionic silver complexes such as AgNO₃ which is spontaneous in action but lose their effectiveness quickly resulting in reinfection.^{137,138} Youngs research group was the first to report Ag-NHC in 2004 for anti-microbial studies.¹³⁹ One example of such series of compound (**XXII**) is shown in Figure 1.11 below. In this work Youngs recorded a highly promising results from this caffeine derived Ag-NHC which showed excellent anti-bacterial activity against drug resistant pathogenic bacteria.^{140,141} The search for better biologically active Ag(I)-NHC complexes led to the synthesis of modified caffeine silver acetate complex.¹³⁴ Gosh and co-workers also synthesized Ag(I)-NHC complexes of 1-

benzyl-3-tert-butylimidazolium chloride and tested on analytically important microorganism.¹⁴² The Ag(I)-NHC complexes derived from 4,5-dichloroimidazole have been synthesized, having water stability for up to three days and this was attributed to the presence of electron withdrawing substituents present on the 4- and 5-positions of the imidazole ring.¹⁴¹ In recent years, varieties of functionalized NHC complexes with bidentate chelating NHCs, tripodal NHCs, pincer type NHCs have also been investigated,^{71,143-147} especially in catalysis while their anti-microbial properties are less explored. The effectiveness of the anti-microbial properties of Ag(I) complexes may be influenced by the type of ligands that bind to Ag(I) ion.¹⁴⁸ It was found that the type of substituents and chain length of alkyl chain have a significant effect on their anti-microbial properties.^{149,150} Modification of NHCs can be easily achieved by introducing functional groups at the nitrogen atoms of the imidazole ring,^{16,146,151} thereby fine-tuning the characteristic features like lipophilicity, charge, solubility of the spacers (bridging groups) and substituents. This has stimulated the design of complexes in favour of reaching a compromise between biological activity and toxic effects.¹⁵¹ Examples of metal based antibiotics are shown in Figure 1.9 below.





Figure 1.9: Sulfadiazine (**XVIII**) and Silver sulfadiazine complex (**XIX**).

A very fascinating characteristic of NHC chemistry is the simplicity with which a number of complexes with similar structures and different lipophilicity (Figure 1.10 & 1.11) can be synthesized by changing the substituents on the imidazolium salts.^{14,16} The lipophilicity of a substance cannot be overlooked as one of the influential parameters in its biological activity.^{134,141,143} The enhanced lipophilicity characters of some compounds have been found to have positive correlation with their anti-bacterial activity.^{152,153}



XX: $m = 2$

(XX, XXI)

XXI: $m = 3$

Figure 1.10: The first Ag(I)-NHC complexes used as anti-microbial agents.







Figure 1.11: Examples of Ag(I)-NHC complexes exhibiting significant anti-microbial activity.

Both functionalized and nonfunctionalized imidazole based NHCs, as well as their metal derivatives of wide structural diversity, have been studied as therapeutic agents for cancer treatment. Specifically, functionalized NHC ligands have attracted special interest from the point of view of tuning the coordination environment around the core metal, because of their flexible chelating nature. In principle, the lipophilicities and reactivities of Ag(I)–NHC complexes can be tuned systematically by changing the attached NHCs or substituents. Therefore in the present work, numerous varieties of Ag(I)–NHC complexes have been synthesized to determine the possible involvement of functional and non-functional substituents present at the N atom(s) of the [benz]imidazolium core.

1.8.3 Biological application of Pd(II)-NHC complexes

A number of complexes based on Pd(II) have been synthesized and their different biological activities have been documented.^{154,155,156} The effect of various palladium complexes on the growth and metabolism of different groups of microbes has been investigated. In 2009 Garoufis et al. reviewed diverse scientific papers on anti-viral, anti-bacterial and antifungal activity of Pd-(II) complexes with various types of ligands (sulfur and nitrogen donor ligands, Schiff base ligands and drugs as ligands).¹⁵⁷ Over the past few years, literature has shown different activities of Pd-(II) complexes against several species of bacteria and fungi.¹⁵⁸⁻¹⁶⁶ Although the biological activity of Pd-based drugs bearing a variety of ancillary ligands has been under intense investigation, only two reports of Pd-(II)-NHC complexes with anti-bacterial activity is found in recent literature (Figure 1.12).^{167,168} Ghosh was the first to explore the cytotoxic capacity of two Pd complexes, **XXVI** and **XXVII** against three human tumor cell lines.¹⁶⁸ To date, numerous Pd(II)–NHC complexes have been reported for various activities. However, this field of chemistry has been